Tim Smith

In this interview, Dr. Chovatiya touched on several important updates and recent developments in the JAK inhibitor space for dermatologists.

In this interview segment, Dr. Nestor speaks on some of his biggest takeaways from his talk ‘What’s Coming Up Next?’ given at the Fall Clinical Dermatology conference.

This interview featured a discussion with Dr. Bhatia on the future of actinic keratosis diagnosis and treatment, as well as advances and important facts for clinicians to remember about risk.

These findings, presented at the Fall Clinical Dermatology conference, resulted from the ADjoin long-term extension study.

This interview at the Fall Clinical Dermatology conference featured a discussion with Dr. Bhatia regarding key insights from his talk ‘What You Need To Know NOW About Actinic Keratosis.’

In this interview on the conference floor at Fall Clinical Dermatology, Dr. Lio discussed the important topic of treating patients with eczema that have skin of color.

This presentation at the Fall Clinical Dermatology conference in Las Vegas explored the topic of advancements in HS treatment.

Though primarily observational, this research’s biggest asset is its experimental design and its exploration of viral stimulus-induced bronchial epithelial cell responses from asthmatic donors being treated with tezepelumab.

This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.

This represented the first in human research focused on assessing the best dosing regimen of mannan-conjugated birch pollen allergoids for those with birch pollen–induced allergic rhinoconjunctivitis.

This new post-hoc analysis of ruxolitinib cream for those with eczema indicates that continued treatment past 8 weeks may lead to further benefit for those with the skin disease.

This segment of Dr. Okoye’s interview featured a set of examples of HS patients’ struggles with access to medication, as well as discussion of potential solutions.

This new data was presented at EADV in Berlin, with the findings of 3 studies expanding the range of effectiveness of this treatment to 140-weeks for patients with eczema.

This interview with Dr. Okoye featured a discussion about her presentation at the SHSA conference, specifically regarding healthcare disparities for HS patients.

In this interview, Dr. Simpson discussed the latest findings presented at EADV in Berlin on the use of tapinarof cream, 1% for adults and children as young as 2 years with eczema.

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

The new data on this drug’s effects on maintenance of clinical response indicates the strength of the treatment for individuals with the immune-mediated skin disease.

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

This new data on the negative impacts of skin disease on individuals in 27 countries in Europe demonstrates the lasting impacts of stigmatization.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

This new data from 27 European countries resulted in several notable findings with regard to the journey of patients with skin disease in various healthcare environments.

This new research could allow for limitations related to safety that could promote mitigation of ambient air pollution and protect those with allergies.

This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.

This new data may help clinicians not to over-treat or over-medicalize with infants that have a SARS-CoV-2 infection.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.

This new synthetic data set could work as a potential resource for training on AI as well as to help facilitate a consensus among clinicians.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

The investigators of this new data note that integration using a standardized process which is EMR-based may be the next thing to move for, to better address the overreporting of penicillin allergy.